Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Acta Paediatr ; 108(12): 2192-2198, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31168848

RESUMEN

AIM: Early-onset neonatal sepsis (EOS) may lead to significant morbidity and mortality, yet the recommended antimicrobials have not changed for many years. We aimed to optimise EOS treatment by examining EOS pathogens, resistance rates and resistance risk factors. METHODS: A retrospective, nationwide cohort study analysing 2010-2015 EOS data in Israel. RESULTS: The 21 participating centres constitute 92% of the total birth cohort (around 180 000 live births/year). Of 549 EOS neonates (0.57/1000 live births), 306 (56%) and 243 (44%) were full-term and preterm, respectively (0.35 vs. 2.94 per/1000 live births). Gram-negative pathogens predominated, especially in preterms. Escherichia coli and Streptococcus agalactiae were most common pathogens (0.2 and 0.19 per 1000 live births, respectively). In 277 Gram-negatives, 16%, 14%, 8% and 3% were gentamicin-resistant, extended-spectrum beta-lactamase (ESBL)-positive, gentamicin-resistant and ESBL-positive, and amikacin-resistant, respectively; preterms had higher resistance rates. No risk factors for antimicrobial resistance were identified. Mortality was reported in 21% of Gram-negative EOS versus 7% of Gram-positive EOS [OR 3.4 (95% CI 1.8-6.2), p < 0.01]. CONCLUSION: In this nationwide study, EOS was caused predominantly by Gram-negatives, with high gentamicin resistance and ESBL phenotype rates, without identifiable resistance risk factors. As EOS is life-threatening, modification of empiric therapy for amikacin-based regimens should be considered, mainly in preterms.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Microbiana , Sepsis Neonatal/epidemiología , Humanos , Recién Nacido , Recien Nacido Prematuro , Israel/epidemiología , Sepsis Neonatal/tratamiento farmacológico , Sepsis Neonatal/microbiología
2.
J Clin Endocrinol Metab ; 102(8): 3050-3055, 2017 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-28637222

RESUMEN

Context: Delayed thyrotropin (TSH) elevation (dTSH) is defined as elevated TSH at the second neonatal screening (after normal TSH levels at the initial screening) in premature, low-birth-weight, and ill newborns, mostly in the neonatal intensive care unit (NICU) setting. The pathogenesis of dTSH is elusive. Objective: To identify the risk factors for dTSH development among newborns in the NICU. Design, Setting, and Patients: A retrospective medical record review of neonates with dTSH was conducted in eight university-affiliated NICUs. Two controls were selected for each patient, matched for sex and birth weight. The risk factors for dTSH were identified by univariate analysis, followed by multivariate analysis. Main Outcome Measures: Maternal variables, types of NICU treatments and procedures, syndromes, and various medical conditions were compared between dTSH patients and their matched controls. Results: We enrolled 100 dTSH patients and 200 matched controls and 46 variables were compared between the two groups. Twelve risk factors for dTSH were identified on univariate analysis: cesarean section, mechanical ventilation, patent ductus arteriosus (PDA), pneumothorax, and administration of cefotaxime, vancomycin, fluconazole, dopamine, ibuprofen, furosemide, insulin, and packed red blood cells. On multivariate analysis, four risk factors were identified: PDA and vancomycin, insulin, and furosemide administration. In 26 twin pairs, in which one twin had dTSH, all variables presented similarly in both twins. Conclusions: Although some variables had direct effects on pituitary-thyroid axis dysfunction, these variables, altogether, reflect the severity of the clinical conditions in the NICU, which is the common basis for dTSH.


Asunto(s)
Hipotiroidismo/diagnóstico , Tirotropina/sangre , Antibacterianos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Antifúngicos/uso terapéutico , Cefotaxima/uso terapéutico , Cesárea , Diuréticos/uso terapéutico , Dopamina/uso terapéutico , Conducto Arterioso Permeable/epidemiología , Transfusión de Eritrocitos , Femenino , Fluconazol/uso terapéutico , Furosemida/uso terapéutico , Humanos , Hipoglucemiantes/uso terapéutico , Hipotiroidismo/sangre , Ibuprofeno/uso terapéutico , Recién Nacido de Bajo Peso , Recién Nacido , Recien Nacido Prematuro , Insulina/uso terapéutico , Unidades de Cuidado Intensivo Neonatal , Masculino , Análisis Multivariante , Tamizaje Neonatal , Neumotórax/epidemiología , Respiración Artificial , Estudios Retrospectivos , Factores de Riesgo , Simpatomiméticos/uso terapéutico , Factores de Tiempo , Vancomicina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA